Ladenburg Thalmann Downgrades Reata Pharmaceuticals to Neutral, Raises Price Target to $172.5
Portfolio Pulse from richadhand@benzinga.com
Ladenburg Thalmann analyst Matthew Kaplan has downgraded Reata Pharmaceuticals from Buy to Neutral, while raising the price target from $122 to $172.5.

July 31, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reata Pharmaceuticals has been downgraded from Buy to Neutral by Ladenburg Thalmann, but the price target has been raised from $122 to $172.5.
The downgrade from Buy to Neutral suggests that the analyst sees limited upside potential for the stock in the near term. However, the raised price target indicates an expectation of long-term growth. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100